FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a compound of formula I
and pharmaceutically acceptable salts and solvates thereof. In the compounds of formula I: Y is selected from Y2 and Y1, which are divalent groups of formula 
or 
, where A1 and A2 independently absent or selected from a group consisting of (C1-C12)alkylene, (C3-C8)cycloalkylene; B is absent or selected from a group consisting of phenylene, optionally substituted with one group selected (C1-C6)alkoxy; C is absent or selected from a group consisting of -O-, -N(R7) - or represents one of the following groups C1-C2 
, where R7 in each case independently represents H or is selected from a group consisting of a straight or branched (C1-C8)alkyl, (C3-C8)cycloalkyl, phenyl, phenyl(C1-C6)alkyl, (C1-C8)alkylcarbonyl, (C3-C8)cycloalkylcarbonyl, phenylcarbonyl, (C1-C8)alkoxycarbonyl, (C1-C8)alkylaminocarbonyl, (C1-C10)alkylsulphanyl and phenylsulphonyl; and where R7 can optionally be further substituted with one group selected from halogen, -CN, (C1-C8)alkyl, halogen (C1-C8)alkyl, phenyl, phenyl (C1-C6)alkyl, (C1-C8)alkoxy, phenyl(C1-C8)alkoxy, (C3-C8)cycloalkyl, which is a saturated monocyclic group, D is absent or is selected from a group consisting of (C1-C12)alkylene and phenylene; n, n', n'' and n''' in each case independently equal to 0 or integer from 1 to 3; E is absent or is selected from -O-, -NR7-, -NR7-C(O)-, -C(O)-NR7-; G is absent or is phenylene or thienylene, optionally substituted with one or two substitutes selected from a group consisting of halogen atoms, (C1-C10)alkyl, phenyl, halophenyl, thienyl and (C1-C10)alkoxy; L is absent or is a divalent group selected from -C(O)-, (C1-C8)alkylcarbonylen and (C2-C8) alkenylcarbonylene; i is 1 or 2; i' is equal to 1 or 2; R1 in each case is independently selected from hydrogen and halogen; s is equal to 0. Also disclosed are a pharmaceutical composition, use of the compound of formula I and a device.
EFFECT: technical result is obtaining novel compounds acting as both muscarinic receptor antagonists and beta-2-adrenergic receptor agonists.
14 cl, 2 tbl, 31 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA-2-ADRENERGIC RECEPTOR AGONIST ACTIVITY | 2013 |
|
RU2661877C2 |
| COMPOUNDS HAVING ANTAGONISTIC ACTIVITY TOWARDS MUSCARINIC RECEPTORS AND AGONIST ACTIVITY TO BETA2-ADRENORECEPTORS | 2012 |
|
RU2606121C2 |
| AMINOPYRAZOLOPYRIMIDINE COMPOUND USED AS INHIBITOR OF TYROSINE KINASE RECEPTOR OF NEUROTROPHIC FACTOR | 2017 |
|
RU2764523C2 |
| 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2021 |
|
RU2810081C1 |
| COMBINED TREATMENT BY A TOLL-LIKE RECEPTOR (TLR7) AGONIST AND A HEPATITIS B VIRUS CAPSID ASSEMBLY INHIBITOR | 2016 |
|
RU2718917C2 |
| COMPOUNDS OF 1-CYANO-PYRROLIDINES AS USP30 INHIBITORS | 2016 |
|
RU2717238C2 |
| NMDA RECEPTOR MODULATORS AND THEIR APPLICATION | 2012 |
|
RU2621049C2 |
| CLASS OF BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUNDS FOR TARGETED DESTRUCTION OF ANDROGEN RECEPTORS AND USE THEREOF | 2020 |
|
RU2825000C2 |
| C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | 2017 |
|
RU2716502C2 |
| ERBB RECEPTOR INHIBITORS | 2019 |
|
RU2810215C2 |
